Holen Sie sich die Stockscreener-App
248.50
0.92%
2.27
Vorhandelsmarkt:
250.00
1.50
+0.60%
Ascendis Pharma A S Aktie (ASND) Neueste Nachrichten
Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Wall Street Zen - MarketBeat
Allspring Emerging Growth Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus
Ascendis Pharma (NasdaqGS:ASND) Stock Turns Profitable As YORVIPATH Drives Growth - simplywall.st
Ascendis Pharma A/S (NASDAQ:ASND) Releases Quarterly Earnings Results, Misses Estimates By $0.68 EPS - MarketBeat
Full Transcript: Ascendis Pharma Q2 2026 Earnings Call - Sahm
Ascendis Pharma posts strong Q2 2026 with €339M revenue, boosts price target to $290 by RBC Capital. - Pluang
Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says - marketscreener.com
RBC Adjusts PT on Ascendis Pharma to $290 From $280, Maintains Outperform Speculative Risk Rating - marketscreener.com
Ascendis Pharma doubles sales, significantly boosting profit - medwatch.com
Ascendis Pharma AS earnings beat by €1.32, revenue topped estimates - Investing.com Nigeria
Ascendis Pharma AS (ASND) (Q2 2026) Earnings Call Highlights: Re - GuruFocus
Ascendis Pharma AS (ASND) (Q2 2026) Earnings Call Highlights: Revenue Doubles to EUR315 ... - Yahoo Finance
Jefferies raises Ascendis Pharma stock price target on Yuviwel strength By Investing.com - Investing.com South Africa
Jefferies raises Ascendis Pharma stock price target on Yuviwel strength - Investing.com Nigeria
Artisan Partners (ASND holder) discloses 2.63M Ascendis Pharma shares in 13G/A - Stock Titan
Ascendis Pharma's Long-Term Potential Intact, Wedbush Says - marketscreener.com
Ascendis Pharma Slides as Investors Weigh Strong Q2 Growth Against One-Time Profit Boost - Quiver Quantitative
Ascendis Pharma A/S Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Ascendis Pharma tops Q2 2026 estimates as launches gain - Investing.com
ASND: Q2 revenue more than doubled year-over-year, fueled by strong TransCon product demand and robust launches - TradingView
Ascendis Pharma A/S reports results for the quarter ended June 30Earnings Summary - TradingView
Ascendis Pharma (ASND) posts Q2 2026 profit on revenue surge and PRV sale - Stock Titan
Ascendis Pharma: Product Revenue Surges 105% To €315 Million As Adjusted Operating Profit Turns Positive - Pulse 2.0
Ascendis Pharma A/S Q2 2026 Earnings Call Transcript - MarketBeat
Ascendis Pharma's Q2 Adjusted Earnings, Revenue Rise - marketscreener.com
Ascendis Pharma (ASND) posts €836M H1 profit and redeems $575M converts - Stock Titan
Ascendis Pharma swings to Q2 profit on revenue doubling, PRV sale - TradingView
Earnings Flash (ASND) Ascendis Pharma Posts Q2 Non-IFRS EPS 0.90 Euros, vs. FactSet Est of 1.80 Euros - marketscreener.com
Ascendis Pharma Reports Second Quarter 2026 Financial Results - The Manila Times
Ascendis Pharma Reports More Than 220 U.S. YUVIWEL Enrollments - Stock Titan
Ascendis Pharma (ASND) issues 15,060 staff warrants at $254.57 strike price - Stock Titan
Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today - Benzinga
Ascendis Pharma A/S expected to post earnings of €1.38 a shareEarnings Preview - TradingView
Ascendis Pharma (NASDAQ:ASND) Combines High Growth Momentum with a Breakout Setup - ChartMill
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $275 - 富途牛牛
Analysts Offer Insights on Healthcare Companies: Progyny (PGNY), Scholar Rock Holding (SRRK) and Ascendis Pharma (ASND) - The Globe and Mail
Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $300 - Moomoo
Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026 - Yahoo Finance
Ascendis Pharma Seeing 'Good Progress' in Achondroplasia Programs, Wedbush Says - Yahoo Finance
Ascendis reports trial data for achondroplasia treatments By Investing.com - Investing.com Nigeria
Ascendis Pharma (ASND) reports new TransCon CNP achondroplasia trial data - Stock Titan
Ascendis Pharma (ASND) Could Be 20% Undervalued Following Its Recent Pullback - simplywall.st
Ascendis Reports 78-Week Data From COACH Trial for Achondroplasia - HCPLive
Ascendis Pharma reports strong growth and safet... - Pluang
Ascendis Announces COACH Week 78 Results and Provides - globenewswire.com
Ascendis plans Aug. 13 webcast before U.S. markets open - Stock Titan
Ascendis Pharma A/S (ASND) Stock Analysis: Unveiling A 26% Upside Potential - directorstalkinterviews.com
Defilade Capital Management L.P. Lowers Position in Ascendis Pharma A/S $ASND - MarketBeat
First Trust Advisors LP Acquires 18,905 Shares of Ascendis Pharma A/S $ASND - MarketBeat
ASND Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Price to book forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Arrowstreet Capital Limited Partnership Invests $20.92 Million in Ascendis Pharma A/S $ASND - MarketBeat
Empowered Funds LLC Acquires 14,438 Shares of Ascendis Pharma A/S $ASND - MarketBeat
Ascendis Pharma (ASND) Could Be 17% Below Fair Value Following Its TransCon Narrative - simplywall.st
Ascendis Pharma Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
86,650 Shares in Ascendis Pharma A/S $ASND Bought by Eagle Health Investments LP - MarketBeat
ASND|Ascendis Pharma A/S|Price:253.204|Chg%:-0.656 - TradingKey
Ascendis Pharma A/S Revenue Breakdown – NASDAQ:ASND - TradingView
Ascendis Pharma A/S (ASND) Cash Flow - TradingKey
Ascendis Pharma A/S (ASND) Valuation: PE, PB & Fair Value Analysis - TradingKey
ASND|Ascendis Pharma A/S|Price:256.235|Chg%:+2.375 - TradingKey
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):